Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Viva Vision Biotech

Request full access

Viva Vision Biotech is a Healthcare Start Up Based In Shanghai

Huangpu, ChinaFounded 2008Biotech & Life Sciences

About Viva Vision Biotech

Viva Biotech Holdings (01873.HK) operates as a contract research organization (CRO) and contract development and manufacturing organization (CDMO), providing a comprehensive suite of services for the pharmaceutical and biotechnology sectors. Founded in 2008 by Cheney Mao, Feng Mao Hua, and Ying Wu, the Shanghai-based company has established itself as a key partner for global biopharmaceutical innovators. The firm's journey includes a significant milestone on May 9, 2019, when it successfully listed on the Hong Kong Stock Exchange, an IPO that was oversubscribed by more than 100 times, signaling strong investor confidence in its business model.

The company's business model is a hybrid, combining a conventional cash-for-service (CFS) structure with a distinctive equity-for-service (EFS) model. Under the CFS model, Viva Biotech generates revenue by providing a wide array of drug discovery and development services. These services span from the early stages of target identification, protein expression, and structure-based drug design to later-stage medicinal chemistry, and API (Active Pharmaceutical Ingredient) development and manufacturing through its subsidiary, Langhua Pharma. The company serves a global client base that includes nine of the top ten largest pharmaceutical companies.

Through its EFS model, managed by its investment arm Viva BioInnovator, the company invests in high-potential, early-stage biotechnology startups by providing its discovery services in exchange for equity. This approach allows Viva to build a diverse portfolio of investments in innovative drug development projects, creating long-term value while supporting emerging companies. As of December 2022, the company had invested in 91 portfolio companies, primarily located in North America and China. Viva Biotech has expanded its technological capabilities over the years, incorporating advanced platforms such as Cryo-Electron Microscopy (Cryo-EM), affinity selection mass spectrometry (ASMS), and an AI-driven drug discovery platform launched in May 2025.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019
Employees
177
Open positions
None listed
Dealroom signal
71.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Investment activity
4 companies, latest Jun 2021
Capital deployed
$91M
Preferred round
SERIES A

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Jun 2023 $210M — Temasek · Highlight Capital · True Light ↗
POST IPO EQUITY✓Other financing May 2023 $14M $230M Sheng Yuan Zhiben · ChiFortune Venture · V-Capital · VVB Fund ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Viva Vision Biotech website traffic

Latest recorded traffic for Viva Vision Biotech is 4.6K monthly website visits, up 109.1% over the last three months. Viva Vision Biotech's team grew 3.5% over the past year.

Latest monthly visits4.6K 3-month web change+109.1% 1-year team growth+3.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Viva Vision Biotech in the Huangpu ecosystem

Live from Dealroom

The Viva Vision Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • JMCR Partners
  • Viva Ventures Biotech Fund

Series B and later15 investors entered at this stage

  • HSG
  • Cenova Capital
  • Zhongjince Investment
  • Betta Pharmaceuticals
  • Xiamen Changrong Investment Management
  • Xizang Ruihai
  • ShenZhen GTJA Investment Group
  • F&H Investment
  • Sheng Yuan Zhiben
  • ChiFortune Venture
  • V-Capital
  • VVB Fund
  • Temasek
  • Highlight Capital
  • True Light

Other known investors3 additional known investors

  • F&H Fund Management
  • Sequoia
  • Shangyuan Capital
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇨🇳 China81.7%
🇺🇸 United States12.7%
🇬🇧 United Kingdom4.2%
🇦🇺 Australia1.4%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Viva Vision Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Viva Vision Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.